TNIK and osteosarcoma: Hirozane et al. identified MAP4K7 as a molecular target in osteosarcoma and demonstrated that its silencing or inhibition via NCB-0846 effectively reduces MAP4K7 expression and inhibits the proliferation of various osteosarcoma cell lines, including U2OS, NOS-10, MNNG/HOS, NOS-1, HsOS, HuO9N2 and NY68.